Skip to main content

Progressive Resistance Training Not Superior for Hip Osteoarthritis

Medically reviewed by Carmen Pope, BPharm. Last updated on April 9, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, April 8, 2024 -- Progressive resistance training (PRT) is not superior to neuromuscular exercise (NEMEX) for improving functional performance in patients with hip osteoarthritis (OA), according to a study published online April 9 in the Annals of Internal Medicine.

Troels Kjeldsen, from Aarhus University Hospital in Denmark, and colleagues examined whether PRT is superior to NEMEX for improving functional performance in a superiority trial involving 160 patients with clinically diagnosed hip OA. The participants were randomly assigned to 12 weeks of PRT or NEMEX (82 and 78 individuals, respectively), with two supervised 60-minute group sessions per week. Change in the 30-second chair stand test (30s-CST) was measured as the primary outcome.

The researchers found that the mean changes from baseline to 12-week follow-up were 1.5 and 1.5 chair stands in the 30s-CST with PRT and NEMEX, respectively. For the Hip Disability and Osteoarthritis Outcome Score (HOOS) pain subscale, the mean changes were 8.6 and 9.3 points with PRT and NEMEX, respectively. For the HOOS quality of life subscale, the mean changes were 8.0 and 5.7 points with PRT and NEMEX, respectively.

"Because PRT was not superior to NEMEX, patients and clinicians may instead, through shared decision-making, choose the preferred type of exercise, which will likely promote motivation, adherence, and effects," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted April 2024

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.